<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <title>Ultibro - Una vez al dia - Breezhaler</title>
    <link rel="stylesheet" href="style.css">
</head>
<body>
<img src="assets/logo_rueda.png" class="logo_rueda">
<div class="container">
    <div class="title">
        <img src="assets/title_text.png">
    </div>

        <div class="dots">
            <img src="assets/dots_bg.png">
        </div>
        
        <div class="rueda">
            <!-- SVG VA AQUI -->
            <?xml version="1.0" encoding="utf-8"?>
            <!-- Generator: Adobe Illustrator 22.1.0, SVG Export Plug-In . SVG Version: 6.00 Build 0)  -->
            <svg version="1.1" id="Layer_1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px"
                viewBox="0 0 532.3 531.6" style="enable-background:new 0 0 532.3 531.6;" xml:space="preserve">
            <style type="text/css">
                .st0{fill:none;stroke:#000000;stroke-width:0.25;stroke-miterlimit:10;}
                .st1{fill:#D1D3D4;}
                .st2{fill:#939598;}
                .st3{fill:#2A9CD8;}
                .st4{fill:#E29B1E;}
                .st5{fill:#003A5D;}
                .st6{fill:#3AAA35;}
                .st7{fill:#EB5E92;}
                .st8{fill:#FFFFFF;}
                .st9{enable-background:new    ;}
                .st10{font-family:'Arial-BoldMT';}
                .st11{font-size:15px;}
                .st12{font-size:20px;}
            </style>
            <path class="st0" d="M364.8,44.8"/>
            <g>
                <circle class="st1" cx="263.4" cy="263.8" r="242.5"/>
                <circle class="st2" cx="263.4" cy="263.8" r="201.2"/>
                <path class="st3" d="M448.4,74.2c-36.1,40-72.3,80.1-108.4,120.1c-5.2-6.1-14.6-15.6-29.1-22.6c-19.2-9.3-36.8-9.4-45.2-8.9V2
                    c22.2,0.3,56.9,3.4,96.1,18.6C402.9,36.5,431.6,58.9,448.4,74.2z"/>
                <path class="st4" d="M531.7,268.2c-0.4,22.9-3.8,58.2-19.4,97.8c-18.1,46-44.4,77.2-61.4,94.5l-114-118.7
                    c7.2-7.5,17.7-20.3,25.1-38.8c5.4-13.6,7.4-25.9,8.1-34.8H531.7z"/>
                <path class="st5" d="M355.6,512.6c-20.3,7-50.4,14.9-87.6,15.6c-40.1,0.8-72.7-6.9-93.9-13.8c16.7-48.8,33.4-97.6,50.2-146.5
                    c8.8,2.5,22.2,5.3,38.6,4.4c15.3-0.8,27.5-4.3,35.8-7.6C317.6,414.1,336.6,463.4,355.6,512.6z"/>
                <path class="st6" d="M195.9,344.6c-38.3,39.3-76.5,78.6-114.8,118c-17.2-16.9-45.9-49.7-63.8-99.4C3.6,324.8,1.5,290.9,2,268.8
                    h158.2c0,8.7,1.3,24.9,9.8,42.6C178.2,328.4,189.3,339.1,195.9,344.6z"/>
                <path class="st7" d="M227.4,171.7c-8.9,4-23.5,11.9-37.2,26.7c-14.2,15.3-21,31.1-24.2,40.4c-51.4-16-102.9-31.8-154.3-47.7
                    c7.2-22.4,23.4-62.9,59.8-101.8c35.5-37.9,73.7-56.7,95.3-65.4C187,73.1,207.2,122.4,227.4,171.7z"/>
                <circle class="st8" cx="266.1" cy="266.8" r="117.3"/>
                <text transform="matrix(0.6146 -0.7888 0.7888 0.6146 89.7938 174.4907)" class="st7a st9"><tspan x="0" y="0" class="st8 st10 st11">RELACIÓN DE</tspan><tspan x="-27.5" y="18" class="st8 st10 st11">COSTO-EFECTIVIDAD</tspan></text>
                <text transform="matrix(0.9315 0.3636 -0.3636 0.9315 271.1506 60.3772)" class="st3a st8 st10 st11">EVIDENCIA CLÍNICA</text>
                <text transform="matrix(0.9315 0.3636 -0.3636 0.9315 275.3068 77.7789)" class="st3a st8 st10 st11">MAS COMPLETA</text>
                <text transform="matrix(1 0 0 1 400.5675 309.7235)" class="st4a st9"><tspan x="0" y="0" class="st8 st10 st11">REDUCCIÓN</tspan><tspan x="0" y="18" class="st8 st10 st11">DE COSTOS</tspan><tspan x="0" y="36" class="st8 st10 st11">ASOCIADOS</tspan><tspan x="0" y="54" class="st8 st10 st11">AL MANEJO</tspan><tspan x="0" y="72" class="st8 st10 st11">DE LA EPOC</tspan></text>
                <text transform="matrix(1 0 0 1 237.4392 440.6893)" class="st5a st9"><tspan x="0" y="0" class="st8 st10 st11">MEJOR</tspan><tspan x="-21.3" y="18" class="st8 st10 st11">DISPOSITIVO</tspan><tspan x="-43.7" y="36" class="st8 st10 st11">PARA INHALACIÓN</tspan></text>
                <text transform="matrix(1 0 0 1 60.6827 329.9169)" class="st6a st9"><tspan x="0" y="0" class="st8 st10 st12">GOLD</tspan><tspan x="6.6" y="24" class="st8 st10 st12">2017</tspan></text>
            </g>
            </svg>
             <!-- SVG TERMINA AQUI -->
        </div>

        <div class="info_st3">
            <img src="assets/info_1.png">
        </div>

        <div class="info_st4">
            <img src="assets/info_2.png">
        </div>

        <div class="info_st6">
            <img src="assets/info_4.png">
        </div>

        <div class="info_st7">
            <img src="assets/info_5.png">
        </div>

        <div class="info_st5">
            <img src="assets/info_3.png">
        </div>
        
        <div class="references_1">
            <b>LABA:</b> Agonista β2 adrenérgico de acción prolongada <br>
            <b>LAMA:</b> Agonista de los receptores muscarínicos de acción prolongada <br>
            <b>ICS:</b> Corticosteroides inhalados <br>
            <b>pMDI:</b> Inhalador presurizado de dosis medida  <br>
        </div>

        <div class="references_2">
                <b>Referencias:</b><br>
                <b>1.</b> Frampton JE. QVA 149 IND/GLY (indacaterol/glycopyrronium fixed-dose  combination):  a review of its use in patients with chronic obstructive pulmonary disease. Drugs. 2014 Mar;74(4):465-88. <br>
                <b>2.</b> Vogelmeier C, Aalamian-Mattheis M, Greulich T, et al S35 Efficacy and safety of the direct switch from various previous treatments to glycopyrronium or indacaterol/glycopyrronium in patients with moderate copd: the crystal study Thorax 2016;71:A22. (1):140.<br>
                <b>3.</b> Vogelmeier C, Gaga M, Aalamian-Mattheiset M, Greulichal T, Marin J, Castellani W. et al. Efficacy and safety of direct switch to Indacaterol/ glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respir Res. 2017 Jul;18:140.<br>
                <b>4.</b> Wedzicha  JA,  Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT. et al.  Indacaterol-Glycopyrronium  versus  Salmeterol-Fluticasone  for  COPD.  N  Engl  J  Med.  2016 Jun;374(23):2222-34.<br>
                <b>5.</b> Chan M-C., Tan EC-H & Yang M-C. Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD. International Journal of Chronic Obstructive Pulmonary Disease. 2018;13: 1079-1088.<br>
                <b>6.</b> Molimard M, Raherison C, Lignot S, Balestra A, Lamarque S, Chartier A, et al. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur Respir J. 2017;49(2).<br>
                <b>7.</b> Global Initiative for Chronic Obstructive Lung Disease (GOLD). Pocket guide to COPD diagnosis, management, and prevention a guide for health care professionals. 2019 report.<br>
                <b>8.</b> Anzueto AR, Vogelmeier CF, Kostikas K, Mezzi K, Fucile S, Bader G. et al.. The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD. International journal of chronic obstructive pulmonary disease. 2017 May;12:1325-1337. 
        </div>

</div>
<script
  src="https://code.jquery.com/jquery-3.4.1.min.js"
  integrity="sha256-CSXorXvZcTkaix6Yvo6HppcZGetbYMGWSFlBw8HfCJo="
  crossorigin="anonymous"></script>
<script>

$(document).ready(function() {
    
    let lastOpened;

    function closeLastOpened() {
         if(lastOpened) {
            $('.info_' + lastOpened).animate({opacity: 0}, 500);
            $('.' + lastOpened).css("transform","scale(1.0)");
            lastOpened = null;
        }
    }
    
    ['st3','st4','st5','st6', 'st7', 'st3a', 'st4a', 'st5a', 'st6a', 'st7a'].forEach(color => {
        $('.' + color).click(function() {
            if(lastOpened && lastOpened == color) {
                closeLastOpened();
            } else {
                    closeLastOpened();
                    if (color=='st3' || color=='st3a') {
                        color = 'st3';
                        $('.info_st3').animate({
                            opacity: 1
                        });
                        $('.info_st3').css('z-index','1')
                    } else if (color=='st4' || color=='st4a') {
                        color = 'st4';
                        $('.info_st4').animate({
                            opacity: 1
                        });
                        $('.info_st4').css('z-index','1')
                    } else if (color=='st5' || color=='st5a') {
                        color = 'st5'
                        $('.info_st5').animate({
                            opacity: 1
                        });
                        $('.info_st5').css('z-index','1')
                    } else if (color=='st6' || color=='st6a') {
                        color = 'st6'
                        $('.info_st6').animate({
                            opacity: 1
                        });
                        $('.info_st6').css('z-index','1')
                    } else if (color=='st7' || color=='st7a') {
                        color = 'st7'
                        $('.info_st7').animate({
                            opacity: 1
                        });
                        $('.info_st7').css('z-index','1')
                    }
                    lastOpened = color;
                    $('.' + color).css("transform","scale(1.1)");
                }
        });
    });
});

</script>
</body>
</html>
